Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

People on the Move: Biotechnology/Biopharma Companies

A2A Pharmaceuticals Inc. named Dr. Sotirios G. Stergiopoulos as president and CEO.

Read More »

BioSpace Readers’ Picks: Top 10 Stories of 2018

Here is a look at BioSpace’s top 10 stories of 2018.

Read More »

Molecular Partners reaches cancer immunotherapy deal with Amgen

Swiss biotechnology company Molecular Partners could earn more than $500 million in payments after striking a deal with U.S. drug giant Amgen to work together in cancer immunotherapy.

Read More »

People On The Move: Biotechnology/Biopharmaceutical

Richard Klinghoffer, Ph.D., was named CEO of Presage Biosciences.

Read More »

People on the Move: Biotechnology/Biopharmaceutical

James (Jim) Robinson is named president and CEO of Alkermes Inc. Robinson joined Alkermes from Astellas US LLC, where he served as president, Americas Operations with responsibility for the company’s operations in North and South America. Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) […]

Read More »

2017 Annual Report: State Of The Bio Industry

R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.

Read More »

Biotech/Biopharma Companies: Financial Snapshot

This chart shows the 2016 and 2015 revenue and R&D figures for some of the world’s leading biotech and biopharma companies.

Read More »

People on the Move: Biotech/Biopharma Companies

Jean-Marie Cuillerot, M.D., has been appointed chief medical officer of Agenus Inc. Dr. Cuillerot initially joined Agenus in 2016 as VP and Global Head of Clinical Development.

Read More »

People on the Move: Biotech/Biopharma Companies

David A. Spiegel, M.D., Ph.D., is now CEO of Kleo Pharmaceuticals Inc.

Read More »

Allergan to Acquire Vitae Pharmaceuticals

Allergan plc will acquire Vitae Pharmaceuticals Inc. for $21.00 per share, in cash, for a total transaction value of approximately $639 million.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom